Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody

Table 5 Other factors than paediatric Crohn’s disease activity index predicting growth, lumbar spine bone mineralisation and lumbar bone mineral apparent density after initiation of adalimumab

Factors	Coefficient	95%CI	P value
ΔHeight SDS
25-OHD	0.6	0-0.04	0.048
ΔBMD SDS
Weight SDS	0.8	0.09-0.6	0.02
BMI SDS	0.7	0.04-0.5	0.03
ΔBMAD SDS
PCDAI at start	-0.7	-0.02-(-0.002)	0.02

SDS: Standard deviation score; 25-OHD: 25-hydroxycholecalciferol; IFX: Infliximab; BMD: Bone mineralisation density; BMAD: Bone mineral apparent density; PCDAI: Paediatric Crohn’s disease activity index.